Related Experiment Video
Updated: Jun 25, 2025
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
43.7K
Vasodilators for Acute Heart Failure - A Systematic Review with Meta-Analysis
Jasmin D Lukoschewitz1, Kristina C Miger2, Anne Sophie O Olesen2
1Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen.
NEJM Evidence
|May 28, 2024
Summary
Vasodilators did not reduce all-cause mortality in acute heart failure patients. However, they were associated with a lower risk of tracheal intubation in this systematic review.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pharmacology
Background:
- Acute heart failure (AHF) presents a significant public health challenge.
- Effective AHF management strategies are crucial for improving patient outcomes.
- This study systematically reviewed evidence on vasodilator use in AHF.
Purpose of the Study:
- To evaluate the efficacy and safety of vasodilators in patients with acute heart failure.
- To synthesize findings from randomized clinical trials (RCTs) through meta-analysis.
Main Methods:
- A comprehensive search of multiple databases (Medline, Embase, etc.) was performed.
- Inclusion criteria focused on RCTs comparing vasodilators with standard care, placebo, or cointerventions.
- Primary outcome was all-cause mortality; secondary outcomes included serious adverse events (SAEs), tracheal intubation, and hospital stay. Risk of bias was assessed.
Main Results:
- The meta-analysis included 46 RCTs with 28,374 patients.
- Vasodilators did not significantly reduce all-cause mortality (RR, 0.95; 95% CI, 0.87-1.04).
- No significant differences were observed in SAEs or length of hospital stay. Vasodilator use was linked to reduced tracheal intubation (RR, 0.54; 95% CI, 0.30-0.99).
Conclusions:
- Vasodilators do not appear to reduce all-cause mortality in patients with acute heart failure.
- The findings suggest a potential benefit in reducing tracheal intubation rates.
- Further research may clarify the role of vasodilators in AHF management.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:23Antihypertensive Drugs: Vasodilators
505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:16Antianginal Drugs: Nitrates and β-Blockers
575
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
575
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570